In a recent merger and acquisitions scenario, it has been announced that Danaher, a multinational conglomerate with a diverse portfolio in life sciences, is moving ahead with the acquisition of Abcam at a price of $5.7 billion. UK-based Abcam provides scientific research universities, biotech, and pharmaceutical industries with reagents and research tools, contributing to drug discovery and diagnostic tests. The details of the acquisition reveal a concordant payout of $24 per share, a modest elevation of 2.7% from Abcam’s recent closing stock price of $23.36.
After a spike in shares in June ensuing the company’s announcement to enhance shareholder value, Abcam was subjected to a revised strategy led by its founder and ex-CEO. The strategy involved exploring alternatives in the business, featuring the possible sale of the company. In this process, Abcam interacted with 30+ identities, narrowing down to 20 potential buyers, and finally settling on the Danaher corporation.
Abcam was established in 1998 by Jonathan Milner, an investor and entrepreneur, who was also its first CEO. Most of its revenue is generated by providing research tools particularly for proteomics (study of proteins), and by developing antibodies licensed to biopharma and diagnostic industries. Despite showing a monetary loss in 2022, the firm reported an annual revenue boost of 14.6%, leading to a total of ~ $455.7 million.
Jonathan Milner, still holding a 6.3% ownership stake in the company, off-boarded from the directorial team in 2020. However, he recently addressed the shareholders, outlining the company’s underperformance since his departure. His plan to seek support to regain executive authorities was put on hold after the strategic adjustment drew attention from merger & acquisition interests.
This acquisition stretches Danaher’s foothold in the life sciences sector. Having four primary business sections, Danaher recorded $31.4 billion in revenue in 2022, $7 billion of which is credited to the life sciences division, where Abcam is also to be inducted.
Dahaher has a history of acquisitions, spending about $637 million in 2022 to acquire around ten businesses. Some major acquisitions include Aldevron, a DNA, mRNA and proteins manufacturer, purchased for $9.6 billion. Furthermore, Danaher bought the life sciences section of GE in 2019 for $21.4 billion.
Analyst Matt Larew pointed out that while the acquisition sits well with Danaher’s portfolio, the agreed price is comparatively lower. He conjectured that Abcam’s negotiation position would have been undermined by Milner’s activist campaign. The transaction is expected to be completed in mid-2024.
To get further details on the move, please follow this link to Medcity News.